Kuliah Farmasi Industri 1 1. General View Drs. Djoharsjah Aptk

Aspek bisnis Industri Farmasi Introduksi/peta bisnis Industri farmasi Research & Dev Manufacturing : BBO – Obat Jadi Pemasaran Industri Vaksin

Aktifitas Industri Farmasi Research Development Manufacturing Bulk Drug Manufacturing Dose Form Marketing Sales Back End Front End Kurang mendapatkan perhatian dan Investasi di Back End sangat sedikit Ketergantungan pada import Tidak tersedia dan didukung oleh SDM mempunyai kompetensi tsb. Kurang adanya Insentif dari Pemerintah Visi Pemerintah/Regulator Farmasi masih merupakan pelengkap dari kesehatan. Visi Industri masih local oriented Lebih banyak investasi Front End Pendanaan di Marketing (Brand Equities/Promosi) lebih dominan AFTA akan meningkatkan investasi disarana produksi (cGMP) dan per syaratan bahan baku (BA-BE) Cost of Quality kurang perhatian

Karakter Industri Farmasi Orientasi usaha Padat modal Padat teknologi Highly regulated (aturan2 ketat) Skala “besar” Multi product Highly competitive Efisiensi : low/medium/high

Risiko Industri Farmasi Perubahan Valuta asing Suku bunga yang tidak terkendali Cash Cycle yang panjang Biaya Riset yang tinggi Product yang mempunyai expired dated Biaya tinggi (Marketing dll) Kemungkinan harga yang dikendalikan Labelisasi Generic mengurangi margin Ketergantungan bahan baku import Investasi Produksi untuk memenuhi persyaratan c GMP

Produk2 industri farmasi Bahan baku Produk ethicals Produk OTC Produk fitokimia Produk2 herbal Produk supplemen Produk biologis

Industri Farmasi Indonesia BUMN (4) pasar pemerintah, tugas menyangga Perusahaan nasional (163): pasar regular/insidentil Perusahaan asing (31) : research based product /produksi sendiri/ produksi dgn lisensi

Kerja sama antar industri fa Transaksi lepas Keagenan Kerja sama pemasaran Lisensi Toll Manufacturing Merger Akuisisi

Jalur Pemasaran Obat PABRIK 198 PBF 2250 Distr Utama Sub Distrib Distr Lepas APOTIK 6000 TOKO OBAT

ORGANISASI INDUSTRI FARMASI

ORGANISASI INDUSTRI FARMASI

Issue aktual C-GMP AFTA ACFTA Pengujian Ba-Be Obat generik Pengendalian harga Pembatasan promosi Etik Pemasaran

PHARMACEUTICAL MARKET 2005 WORLD MARKET 565,9 BILLION US $ ASIA, AFRICA & AUSTRALIA ( exclusive JAPAN ) 46,4 BILLION US $ Sumber : IMS Health

Global pharma sales by region 2005 (excluded un audited market) World audited Market 2005 Sales % share % Growth   bn US $ North America 265.7 46.95% 5.2% Europe 169.5 29.95% 7.1% Japan 60.3 10.66% 6.8% Asia, Africa & Australia 46.4 8.20% 11.0% Latin America 24.0 4.24% 18.5% Total Market 565.9 100.00% 6.9%

Leading Manufacturer by global sales 2005 (excluded un audited market) Rank Audited Manufacturer Nationality 2005 Sales bn US$ % Growth 1 Pfizer USA 47.7 -7% 2 GSK UK 34.9 5% 3 Sanofi Aventis France 30.5 8% 4 Novartis Switzerland 28.7 11% 5 J&J 25.4 0% 6 Astra Zeneca 24.2 9% 7 Merck & Co 23.6 -3% 8 Roche 19.9 17% 9 Abbott 15.7 10 BMS 14.8 -6%  

global sales 2005 (excluded un audited market) Leading therapy classes Leading Product Sales No Therapy class Sales 2005 Sales % Growth 1 Cholesterol & trig. reducer 32.6 7 2 Anti ulcerants 26.9 4 3 Antidepressants 19.9 -4 Anti psychotics 16.3 11 5 Erythropoetins 12.4 6 Calcium Antagonists plain 12.0 Anti epileptics 11.7 8 All anti neoplastics 11.5 31 9 Oral anti diabetics 10.8 10 Platelet aggregation inhib. 9.8   No Product Sales 2005 Sales % Growth 1 Lipitor 12.9 6.4 2 Plavix 5.9 16.0 3 Nexium 5.7 16.7 4 Seretide/ Advair 5.6 19.0 5 Zocor 5.3 -10.7 6 Norvase 5.0 2.5 7 Zyprexa 4.7 -6.8 8 Risperdal 4.0 12.6 9 Ogastro/ Prevacid 0.9 10 Effecxor 3.8 20.1  

Indonesian Pharma Market

Pasar farmasi Indonesia Tahun 2007 : US $ 2.8 Milyar Tahun 2012 : US $ 4.2 M (prakiraan Terdiri atas : - Pasar Obat Bebas (OTC) - Pasar obat resep (Ethicals)

Trend Indonesian Pharmaceutical Market Milyar Rupiah Million US $ Source : IMS Health

Trend Growth Indonesian Pharma Market Trend Indonesian Drug Expend per capita ( US $ ) Source : IMS Health

Share OTC & Ethical - Pharma Market Reg.Product 15,911 Item Value Units Source : IMS Health

Share National Comp.& MNC Pharma Market 2000 2005 Source : IMS Health

Drug expenditure grows exponentially with GDP per capita Australia Taiwan Korea Vietnam New Zealand Singapore Indonesia Philippines Hong Kong Thailand Can’t find source. Malaysia China India

ASEAN PHARMA MARKET COUNTRY 2003 2004 2005 2006* 2007* Indonesia The South East Asian Pharmaceutical Market (2003-2007) US$ million at Ex-Manufacturer Price Using Forecast Exchange Rates COUNTRY 2003 2004 2005 2006* 2007* Indonesia 1670.2 1947.6 2282.2 2579.7 2889.7 Philippines 1191.7 1291.1 1390.9 1500.6 1590.6 Thailand 997.7 1124.1 1250.2 1402.6 1581.4 Vietnam 388.4 417.6 447.6 483.0 520.2 Malaysia 376.3 392.9 403.3 422.5 442.2 Singapore 273.9 304.3 342.2 387.3 433.4 Cambodia 82.2 87.7 93.2 98.7 104.3 Myanmar (Burma) 39.3 40.4 41.5 42.6 43.8 Laos 2.9 3.1 3.3 3.5 3.7 Brunei 1.6 1.7 1.8 Total Market Size 5024.2 5610.4 6256.1 6922.3 7611.1 This is the prognosis of the pharma market in East & South East Asia Indonesia with growth almost 15% could be a potential market of pharma * Forecast Source : IMS

Pangsa pasar 2004 (Rp. T) Sanbe 1.537 Kalbe 1.222 Dexa 1.153 Tempo 0.947 Bintang 7 0.875 Pfizer 0.762 KF 0.516 Konimex 0.516

PERBANDINGAN PERUSAHAAN FARMASI Tbk 2005 Uraian INAF Phapros Tempo Darya V Revenue 684,040 371,412 2,497,974 540,437 Margin 199,271 185,147 1,084,818 355,547 Biaya Usaha 164,190 149,294 731,335 279,292 Laba Usaha 35,081 35,853 353,483 76,256 Laba seb.pajak 16,039 37,329 404,924 106,051 Laba bersih 9,595 26,025 304,092 71,576 Laba per saham 3 310 660 128 100.00% 29.13% 49.85% 43.43% 65.79% 24.00% 40.20% 29.28% 51.68% 5.13% 9.65% 14.15% 14.11% 2.34% 10.05% 16.21% 19.62% 1.40% 7.01% 12.17% 13.24%

Ranking Perusahaan Farmasi Fortune tahun 2004 Company Sales Profit Asset Market Value   23 Pfizer 52,516 11,360 123,684 197,990 63 Johnson & Johnson 47,348 8,509 47,589 194,683 70 Glaxo S.Kline 39,077 8,261 43,336 140,385 74 Novartis 30,618 6,251 52,280 122,072 81 Roche Group 27,432 5,825 50,025 107,994 107 Merck & Co 22,939 5,813 40,580 70,297 145 Astra Zeneca 22,362 3,980 25,616 64,735 146 Abbot Lab 19,680 3,236 26,715 71,624 169 Bristol M Squibb 19,380 2,388 26,237 48,699 182 Wyeth 17,358 1,234 29,727 54,462 191 Eli Lily & Co 13,858 1,810 24,867 63,372 194 Amgen 10,550 2,363 29,221 78,253

Ranking Perusahaan Farmasi Fortune tahun 2004 Company Sales Profit Asset Market Value   218 Walgreen 38,677 1,438 14,150 73,746 232 Takeda 10,408 2,733 22,325 42,528 268 C V S 30,594 959 14,492 19,980 293 Sanofi - Aventis 10,123 2,611 10,898 113,154 459 Solvay Group 10,688 664 12,844 9,865 479 Bayer Group 35,933 -1,712 45,468 27,322 581 Novo Nordisk 5,295 914 6,687 18,478 598 Schering Group 6,658 678 6,779 13,921 657 Teva Pharmaceutical 4,980 344 9,632 18,692 660 Yamanouchi Pharma 4,897 575 8,454 11,665 704 Sankyo Pharma 5,713 416 8,751 9,741 743 Schering Plough 8,272 -946 15,102 27,938 843 Quest Diagnostic 5,127 499 4,204 9,751 1303 Rite Aid 16,872 133 5,678 1,822 1936 Ranbaxy Lab 967 160 931 4,347

Thank You